- Home
- ESS vs ILMN Comparison
ESS vs ILMN Comparison
Compare ESS & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESS
- ILMN
- Stock Information
- Founded
- ESS 1971
- ILMN 1998
- Country
- ESS United States
- ILMN United States
- Employees
- ESS N/A
- ILMN N/A
- Industry
- ESS Real Estate Investment Trusts
- ILMN Medical Specialities
- Sector
- ESS Real Estate
- ILMN Health Care
- Exchange
- ESS Nasdaq
- ILMN Nasdaq
- Market Cap
- ESS 17.9B
- ILMN 15.9B
- IPO Year
- ESS 1994
- ILMN 2000
- Fundamental
- Price
- ESS $281.59
- ILMN $79.58
- Analyst Decision
- ESS Hold
- ILMN Buy
- Analyst Count
- ESS 20
- ILMN 18
- Target Price
- ESS $304.83
- ILMN $138.22
- AVG Volume (30 Days)
- ESS 464.7K
- ILMN 1.9M
- Earning Date
- ESS 04-29-2025
- ILMN 05-08-2025
- Dividend Yield
- ESS 3.60%
- ILMN 3.90%
- EPS Growth
- ESS 27.78
- ILMN N/A
- EPS
- ESS 10.45
- ILMN N/A
- Revenue
- ESS $1,861,154,000.00
- ILMN $4,372,000,000.00
- Revenue This Year
- ESS $3.48
- ILMN N/A
- Revenue Next Year
- ESS $4.03
- ILMN $4.51
- P/E Ratio
- ESS $27.33
- ILMN N/A
- Revenue Growth
- ESS 9.74
- ILMN N/A
- 52 Week Low
- ESS $243.85
- ILMN $68.70
- 52 Week High
- ESS $317.73
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- ESS 49.09
- ILMN 53.52
- Support Level
- ESS $283.72
- ILMN $73.86
- Resistance Level
- ESS $288.52
- ILMN $79.22
- Average True Range (ATR)
- ESS 6.05
- ILMN 2.60
- MACD
- ESS 1.75
- ILMN 0.84
- Stochastic Oscillator
- ESS 53.96
- ILMN 88.40
About ESS Essex Property Trust Inc.
Essex Property Trust owns a portfolio of 256 apartment communities with over 62,000 units. The company focuses on owning large, high-quality properties on the West Coast in the urban and suburban submarkets of Southern California, Northern California, and Seattle.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.